Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 256 participants.

Also called NCT03198793

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 256 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03198793
Other papers using this trial's data
  • Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins Circulation, 2019-07-09 DOI, PubMed 31014072

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03198793. Allocation not applicable; no masking; primary purpose treatment. Start 2017-10-13 (actual); primary completion 2018-10-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins
Acronym
NEW-HOPE
Condition
Hypertension
Intervention (Drug)
QGC001
Lead sponsor
Quantum Genomics SA (class: industry)

Record details

Record id
cardio:ct-nct03198793
Content hash
cf7e111752c5ddc068c67f892e946afe670ee80b714e37e70336c1802d9bd7ae